Supernus Pharmaceuticals, Inc.
SUPN
Rangering i aksjer
#5560
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Aksjekurs
$41.01
Sist synkronisert: 2026-10-21
Markedsverdi
$2.39B
Endring (1 dag)
-0.55%
Endring (1 år)
-18.33%
Land
US
Handel Supernus Pharmaceuticals, Inc. (SUPN)
Kategori
Healthcare
Aksjeprishistorikk for Supernus Pharmaceuticals, Inc. (SUPN)
Høyeste sluttskurs: $41.69 den 2026-10-01
Laveste sluttskurs: $40.92 den 2018-01-01
Laveste sluttskurs: $40.92 den 2018-01-01
Aksjeprishistorikk for Supernus Pharmaceuticals, Inc. fra 2018 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -0.51% |
| 2025 | 31.56% |
| 2024 | 30.76% |
| 2023 | -22.16% |
| 2022 | 10.88% |
| 2021 | 36.92% |
| 2020 | -26.72% |
| 2019 | -18.72% |
| 2018 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $161.71 | 20.94% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $223.29 | 30.39% |
CH
|
|
| $18.49 | -3.70% |
IN
|
